Sign in
BCTXW Stock Price, Chart, Stats & News
BriaCell Therapeutics Corp.
Save
BriaCell Therapeutics Corp. (BCTXW) does not currently pay a dividend.
1,695
Market cap
–
Current P/E
–
Forward P/E
BCTXW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.44% |
ROA | -100.67% |
ROE | -205.87% |
D/E | – |
Interest coverage ratio | -541.95x |
BCTXW valuation
P/E | – |
P/S | – |
P/B | 0.25x |
P/CF | -0.28x |
P/FCF | -0.19x |
P/OCF | -0.28x |
PEG | 0.03x |
EV multiple | -1.21x |
About
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, currently in Phase 3, dedicated to revolutionizing cancer treatment through its innovative cellular immunotherapies. Its flagship product, Bria-IMT, is currently undergoing a pivotal Phase 3 clinical trial for advanced breast cancer, where it's being evaluated in combination with an immune checkpoint inhibitor. Beyond this lead candidate, the company is also advancing the development of personalized, off-the-shelf treatments designed to combat breast, prostate, and various other forms of cancer.
Similar securities
Based on sector and market capitalization
Report issue